ASX up, Greenhy2 soars 300pc
The ASX ended the week on a high note as Woolies and Coles soared. Miners took a hit, however, after Trump’s exec order.
Stockhead
Aussie moguls’ family offices fuel sustainability
Family offices are booming in the Asia-Pacific, backing sustainability projects with big players like Grok, Tattarang, and Wedgetail leading.
Woolies, Coles cleared; miners rattled by Trump
The local market has swung between green and red on Friday. At lunch time AEDT, the ASX 200 index had bounced back by 0.3%.
Broker backs Boss to beat shorts
Uranium miner Boss is the most shorted stock on the ASX. But broker Euroz has initiated with a hefty price target.
More Stories
ASX biotechs take on traumatic brain injury
Advocates of TBI awareness are pushing for better care while ASX companies drop devices and drugs that are stepping up the fight.
ASX up 1.2pc as tech shines, jobs dip
ASX rises +1pc, Nanosonics jumps after FDA approval, and Aussie job numbers dip, sparking rate cut hopes.
Silver bulls lead ASX explorers higher
Gold has been grabbing the headlines as it ventures above the US$3000/oz mark, but the quiet achievers have been silver stocks.
Nanosonics shares soar on FDA approval
The US Food and Drug Administration has approved Nanosonics’ next-generation medical probe sterilising device, dubbed Coris.
WCN closer to Great Bear drilling
White Cliff Minerals has executed an exploration agreement with the Délınę Got ̨ ’ınę government that facilitates exploration at Great Bear.
Imricor raises $70 million for growth
Imricor Medical Systems has received firm commitments to raise $70 million via a strongly supported placement to new and existing institutional and sophisticated investors.
ASX rebounds, Nanosonics gets FDA nod
The ASX has bounced back after Wall Street’s surge. Meanwhile Nanosonics has soared on FDA approval, and Bitcoin is back above $86k while gold grabbed another personal best.
Time for a bit of ‘portfolio medicine’
In a softening market, Precision Funds Management’s Dermot Woods and Andy Clayton are eyeing off opportunities to upgrade their portfolio.
Big pharma bet pays off for Clever Culture
Biotech Clever Culture Systems has made a significant strategic pivot to target big pharma customers, and it looks like the right move.
BTR’s maiden Laverton gold pour
Brightstar has completed its first gold pour for CY25 with revenue ramping up to support exploration plans.
Original URL: https://www.thechronicle.com.au/business/stockhead/page/2